How to buy Bausch + Lomb stock in Canada

Bausch + Lomb Corporation, an eye health company responsible for producing popular contact lens brands like Biotrue and Soflens, is planning to go public. Here's what we know—and how to buy Bausch + Lomb Corporation stock in Canada when it launches.

Our top picks for where to buy Bausch + Lomb stock

Buy Bausch + Lomb Corporation stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Note: The dollar amounts in the table below are in Canadian dollars.

Finder Score for stock trading platforms

To make comparing even easier we came up with the Finder Score. Trading costs, account fees and features across 10+ stock trading platforms and apps are all weighted and scaled to produce a score out of 10. The higher the score the better the platform - simple.

Read the full methodology

Related: Compare the best stock trading platforms in Canada

Bausch + Lomb stock price (Toronto Stock Exchange (TSX): BLCO)

Use our graph to track the performance of BLCO stocks over time.

Bausch + Lomb stocks at a glance

• Key figures

Information last updated 2025-06-07.

Latest market close	C$17.09
52-week range	C$14.56 - C$29.37
50-day moving average more info button	C$16.83
200-day moving average more info button	C$23.11
Wall St. target price	C$24.27
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	C$-1.40

Is it a good time to buy Bausch + Lomb stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Dive deeper: Our picks for the best stocks to buy right now in Canada

Is Bausch + Lomb stock undervalued or overvalued?

Valuing Bausch + Lomb stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Bausch + Lomb's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Bausch + Lomb's PEG ratio

Bausch + Lomb's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.7019. A low ratio can be interpreted as meaning the stocks offer better value, while a higher ratio can be interpreted as meaning the stocks offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Bausch + Lomb's future profitability. By accounting for growth, it could also help you if you're comparing the stock prices of multiple high-growth companies.

Bausch + Lomb's EBITDA

Bausch + Lomb's EBITDA (earnings before interest, taxes, depreciation and amortisation) is C$562 million.

The EBITDA is a measure of a Bausch + Lomb's overall financial performance and is widely used to measure a its profitability.

Bausch + Lomb financials

Revenue TTM	C$4.8 billion
Gross profit TTM	C$2.9 billion
Return on assets TTM	0.61%
Return on equity TTM	-5.36%
Profit margin	-7.5%
Book value	C$18.00
Market Capitalization more info button	C$5.7 billion
EBITDA more info button	C$562 million

TTM: trailing 12 months

Bausch + Lomb stock dividends

We're not expecting Bausch + Lomb to pay a dividend over the next 12 months.

Bausch + Lomb stock price volatility

Over the last 12 months, Bausch + Lomb's stocks have ranged in value from as little as C$14.56 up to C$29.37. A popular way to gauge a stock's volatility is its "beta."

Beta is a measure of a stocks volatility in relation to the market. The market (TO average) beta is 1, while Bausch + Lomb's is 0.562. This would suggest that Bausch + Lomb's stocks are less volatile than average (for this exchange).

Bausch + Lomb overview

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lenses that are indicated for therapeutic use and provides optical correction during healing. It also offers contact lens care products, eye vitamins, mineral supplements, and over-the-counter eye drops that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. The Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery. The company sells its products and services through direct sales forces and independent distributors.

Related: New to stock trading? Compare brokers and get tips for investing.

Frequently asked questions

What percentage of Bausch + Lomb is owned by insiders or institutions?
Currently 88.167% of Bausch + Lomb stocks are held by insiders and 11.007% by institutions. How many people work for Bausch + Lomb?
Latest data suggests 13,500 work at Bausch + Lomb. When does the fiscal year end for Bausch + Lomb?
Bausch + Lomb's fiscal year ends in December. Where is Bausch + Lomb based?
Bausch + Lomb's address is: 520 Applewood Crescent, Vaughan, ON, Canada, L4K 4B4 What is Bausch + Lomb's ISIN number?
Bausch + Lomb's international securities identification number is: CA0717051076 What is Bausch + Lomb's CUSIP number?
Bausch + Lomb's Committee on Uniform Securities Identification Procedures number is: 071705107

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.